within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01E_OtherCardiacPreparations.C01EB15_Trimetazidine;

model Trimetazidine
  extends Pharmacolibrary.Drugs.ATC.C.C01EB15;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01EB15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Trimetazidine is a metabolic anti-ischemic agent used primarily in the treatment of angina pectoris. It works by improving myocardial glucose utilization through inhibition of fatty acid metabolism. Trimetazidine is not commonly used in the United States, but is approved in Europe and several other countries for stable coronary artery disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Liu, WF, et al., &amp; Zhao, GP (2012). [Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. <i>Zhonghua xin xue guan bing za zhi</i> 40(12) 1041–1044. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23363721/\">https://pubmed.ncbi.nlm.nih.gov/23363721</a></p></li><li><p>McClellan, KJ, &amp; Plosker, GL (1999). Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. <i>Drugs</i> 58(1) 143–157. DOI:<a href=\"https://doi.org/10.2165/00003495-199958010-00016\">10.2165/00003495-199958010-00016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10439934/\">https://pubmed.ncbi.nlm.nih.gov/10439934</a></p></li><li><p>Alam, N, et al., &amp; Aqil, M (2015). Mucoadhesive elementary osmotic pump tablets of trimetazidine for controlled drug delivery and reduced variability in oral bioavailability. <i>Drug development and industrial pharmacy</i> 41(4) 692–702. DOI:<a href=\"https://doi.org/10.3109/03639045.2014.900076\">10.3109/03639045.2014.900076</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24669975/\">https://pubmed.ncbi.nlm.nih.gov/24669975</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Trimetazidine;
